Skip to main content

Vincristine liposome Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 26, 2023.

Applies to vincristine liposome: intravenous suspension.

Warning

Intravenous route (Suspension)

VinCRIStine sulfate liposome is for IV use only and is fatal if given by other routes. Death has occurred with intrathecal use. VinCRIStine sulfate liposome injection has different dosage recommendations than vinCRIStine sulfate injection. Verify drug name and dose before preparation and administration to avoid overdosage.

Serious side effects

Along with its needed effects, vincristine liposome may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking vincristine liposome:

More common

Less common

Other side effects

Some side effects of vincristine liposome may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to vincristine liposome: intravenous kit.

Cardiovascular

Common (1% to 10%): Hypotension, cardiac arrest, vascular disorder[Ref]

Gastrointestinal

Very common (10% or more): Nausea (52%), diarrhea (37%), decreased appetite (33%)

Common (1% to 10%): Constipation, abdominal pain, ileus/colonic pseudo-obstruction[Ref]

General

Side effects that have resulted in non-leukemia related deaths: Brain infarct, intracerebral hemorrhage, liver failure, multisystem organ failure, pneumonia and septic shock, respiratory failure, pulmonary hemorrhage, sudden cardiac death[Ref]

Hematologic

Very common (10% or more): Febrile neutropenia (38%), neutropenia (31.3%), anemia (34%), thrombocytopenia (16.9%)

Frequency not reported: Neutropenia, thrombocytopenia[Ref]

Metabolic

Frequency not reported: Increased aspartate aminotransferase, tumor lysis syndrome[Ref]

Musculoskeletal

Frequency not reported: Asthenia, muscular weakness, musculoskeletal pain[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (39%), insomnia (32%)

Common (1% to 10%): Peripheral sensory and motor neuropathy, decreased vibratory sense, facial palsy, hyporeflexia, asthenia[Ref]

Other

Very common (10% or more): Pyrexia (15%), fatigue (12%)[Ref]

Psychiatric

Frequency not reported: Mental status changes[Ref]

Respiratory

Common (1% to 10%): Respiratory distress, respiratory failure, pneumonia[Ref]

Immunologic

Common (1% to 10%): Septic shock, staphylococcal bacteremia[Ref]

Local

Frequency not reported: Extravasation tissue injury[Ref]

Hepatic

Frequency not reported: Hepatic toxicity[Ref]

Oncologic

Very common (10% or more): Pyrexia (43%), fatigue (41%)

Frequency not reported: Pain, septic shock, staphylococcal bacteremia[Ref]

References

1. Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc. PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.